Achaogen, Inc., a late-stage biopharmaceutical company developing antibacterials for multi-drug resistant (MDR) gram-negative infections, said that the U.S. FDA has classified the outcome of its fourth quarter 2017 re-inspection of Pfizer’s McPherson, KS facility as Voluntary Action Indicated (VAI). The company’s new drug application (NDA) for plazomicin is currently under regulatory review, and the change to VAI status provides a clear regulatory path for approval for plazomicin out of the McPh...